


Patent Docket P0871P3D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|  |  |
|--|--|
| In re Application of<br><br>Dan L. Eaton et al.<br><br>Serial No.: 08/422,548<br><br>Filed: 13 April 1995<br><br>For: MPL LIGAND | Group Art Unit: 1804<br><br>Examiner: Unassigned<br><br><div style="border: 1px solid black; padding: 5px;"><p style="text-align: center; margin: 0;">CERTIFICATE OF MAILING</p><p style="font-size: small; margin: 0;">I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p><p style="text-align: center; margin: 5px 0;">February 20, 1996</p><p style="text-align: center; margin: 0;"><br/>Elisa R. Hamby</p></div> |
|--|--|

**TRANSMITTAL LETTER**

BOX SEQUENCE LISTING  
Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

In response to the Communication dated 10/19/95, transmitted herewith are the following documents:

1. Petition for Extension of Time.
2. Second Preliminary Amendment.
3. Certificate re: Sequence Listing w/  
Substitute Sequence Listing and diskette.
4. Copy of Notice to Comply.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 0630.

Respectfully submitted,  
GENENTECH, INC.

Date: February 20, 1996

By: 

Daryl B. Winter  
Reg. No. 32,637

460 Pt. San Bruno Blvd.  
So. San Francisco, CA 94080-4990  
Phone: (415) 225-1249  
Fax: (415) 952-9881

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990, and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7.

Other: \_\_\_\_\_

**Applicant must provide:**

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123  
For CRF submission help, call (703) 308-4212  
For PatentIn software help, call (703) 557-0400

**Please return a copy of this notice with your response.**